Clinical Trials

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

73 enrolled

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT00017433 2020-10-06

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00473590 2017-06-14

AMBER

102 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

50 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00256880 2017-01-18

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

100 enrolled

GenitourinaryPlasma cell

Carcinoma, Renal Cell, Neoplasms, Plasma Cell

NCT00431340 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

4 enrolled

Multiple Myeloma, Bone Marrow Neoplasms, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

53 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01500161 2013-11-25

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

1 enrolled

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00022282 2013-02-28

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00087867 2010-10-18

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

62 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00229203 2009-12-24

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

51 enrolled 10 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00095277 2009-03-13

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Classical hematologyPlasma cell

220 enrolled

Anemia, Neoplasms, Plasma Cell

NCT00096837 2006-06-08

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

25 enrolled